$PTX $PTX.AX BULLISH #LONG #ASX Chart is shaping for a bullish continuation. Short term target is 36-39c
#dyor #biotech
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.010 AUD
−8.24 M AUD
0.00 AUD
793.88 M
About PRESCIENT THERAPEUTICS LIMITED
Sector
Industry
CEO
Steven Yatomi-Clarke
Website
Headquarters
South Melbourne
Founded
1986
ISIN
AU000000PTX3
FIGI
BBG000J4RZJ3
Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986, and is headquartered in South Melbourne, Australia.
$PTX - #LONG #Bullish #Uptrending Below 7.8 short otherwise accumulate and go #LONG #Bullish Put a trailing stop and let the Market stop you out.
Buy: PTX.AXOn watch
Ascending triangle base forming
Price tracking above 20MA
May have big resistance at 5.9c
Need more volume to kick on
$PTX.AX - Bullish on close - LONGMassive bullish volume, creating demand. Could gap up on Monday.
Really cool trade to take. Probable upside from here.
$PTX - Go Long - Incoming News - M&A activityIncoming news on Clinical Trials in a hot M&A sector. Still Relatively cheap at $15 m MC. Solid Science and management at the wheel.
$PTX - Prescient Therapeutics - Strong news on cancer treatmentPopped up on my volume alerts and bought on the pullback. Went as high as 10 cents on some pretty strong news!
ANNOUNCEMENT:
================================
Melbourne, Australia (10 December 2018): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) is pleased to
Interesting VSo this is another clinical stager.... Coming along with PTX100 and PTX200 studied for breast cancer and incombination with citarabine for acute myeloid leukemia. Technically all levels above 0,13 are a buy!
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PTX is 0.051 AUD — it has increased by 6.25% in the past 24 hours. Watch PRESCIENT THERAPEUTICS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange PRESCIENT THERAPEUTICS LIMITED stocks are traded under the ticker PTX.
PTX stock has risen by 2.00% compared to the previous week, the month change is a 27.50% rise, over the last year PRESCIENT THERAPEUTICS LIMITED has showed a −17.74% decrease.
PTX stock is 8.33% volatile and has beta coefficient of 0.23. Track PRESCIENT THERAPEUTICS LIMITED stock price on the chart and check out the list of the most volatile stocks — is PRESCIENT THERAPEUTICS LIMITED there?
Today PRESCIENT THERAPEUTICS LIMITED has the market capitalization of 38.66 M, it has increased by 16.67% over the last week.
Yes, you can track PRESCIENT THERAPEUTICS LIMITED financials in yearly and quarterly reports right on TradingView.
PRESCIENT THERAPEUTICS LIMITED is going to release the next earnings report on Feb 21, 2025. Keep track of upcoming events with our Earnings Calendar.
PTX net income for the last half-year is −4.62 M AUD, while the previous report showed −3.62 M AUD of net income which accounts for −27.61% change. Track more PRESCIENT THERAPEUTICS LIMITED financial stats to get the full picture.
No, PTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PRESCIENT THERAPEUTICS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PRESCIENT THERAPEUTICS LIMITED technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PRESCIENT THERAPEUTICS LIMITED stock shows the sell signal. See more of PRESCIENT THERAPEUTICS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.